News

Polypill treatment for heart disease offers high value in low-income, underserved population

14 Jan: Polypill treatment for heart disease offers high value in low-income, underserved population

Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to research published in JAMA Cardiology. Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a

Adding depression, anxiety measures to CVD prediction model has little impact

14 Jan: Adding depression, anxiety measures to CVD prediction model has little impact

Inclusion of measures of depression and anxiety in the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) prediction model has little additional impact on risk classification of cardiovascular disease (CVD), according to a study published online Jan. 13 in the Canadian Medical Association Journal. Shinya Nakada, M.P.H., from the University of Glasgow in

11 Jan: Empathy-focused Calls Boost Diabetes Self-Care

TOPLINE: Empathetic telephone calls by laypeople may improve glycemic control in patients with uncontrolled diabetes and low income, particularly in those with subclinical depressive symptoms. METHODOLOGY: Patients were stratified by baseline depressive symptom scores ≥ 5 (a cutoff that includes subclinical depressive symptoms) and < 5 and randomly assigned to an intervention group (n =

09 Jan: Intensive BP Control May Benefit CKD Patients in Real World

TOPLINE: The cardiovascular benefits observed with intensive blood pressure (BP) control in patients with hypertension and elevated cardiovascular risk from the Systolic Blood Pressure Intervention Trial (SPRINT) can be largely replicated in real-world settings among patients with chronic kidney disease (CKD), highlighting the advantages of adopting intensive BP targets…

05 Jan: ESG Plus Lifestyle Intervention Shows Promise for MASH

TOPLINE: Endoscopic sleeve gastroplasty (ESG) combined with lifestyle changes leads to significant weight loss and improves liver health in patients with metabolic dysfunction–associated steatohepatitis (MASH) and obesity over 72 weeks. METHODOLOGY: A prospective randomized trial was conducted in four centers in Spain from April 2018 to December 2020 to assess the effectiveness and safety of